Delving into the Latest Updates on LIJTF-500025 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

LIMK1 x LIMK2

Mechanism

LIMK1 inhibitors(LIM domain kinase 1 inhibitors), LIMK2 inhibitors(LIM domain kinase 2 inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

University of Cardiff

Active Organization

University of Cardiff

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

LIM domain kinases 1 and 2 (LIMK1 and LIMK2) regulate actin dynamics and subsequently key cellular functions such as proliferation and migration. LIMK1 and LIMK2 phosphorylate and inactivate cofilin leading to increased actin polymerization. As a result, LIMK inhibitors are emerging as a promising treatment strategy for certain cancers and neurological disorders. High-quality chemical probes are required if the role of these kinases in health and disease is to be understood. To that end, we report the results of a comparative assessment of 17 reported LIMK1/2 inhibitors in a variety of in vitro enzymatic and cellular assays. Our evaluation has identified three compounds (TH-257, LIJTF500025, and LIMKi3) as potent and selective inhibitors suitable for use as in vitro and in vivo pharmacological tools for the study of LIMK function in cell biology.

100 Deals associated with LIJTF-500025

Login to view more data